Core Viewpoint - The stock of HeartFlow Medical-B (02160) rose over 4% ahead of its mid-year earnings announcement, with expectations of a significant reduction in net losses for the first half of 2025 compared to the previous year [1] Group 1: Earnings Announcement - HeartFlow Medical-B plans to hold a board meeting on August 28 to consider and approve its mid-year earnings [1] - The company anticipates a net loss of no more than RMB 10 million for the first half of 2025, representing a year-on-year decrease of at least 83% [1] Group 2: Revenue Drivers - The reduction in net losses is attributed to the sales of the VitaFlow Liberty transcatheter aortic valve and its delivery system in over 20 countries, resulting in more than a twofold increase in overseas revenue [1] - The commercial progress of the AnchorMan left atrial appendage occluder system and its guiding system in China has been steady, with the product obtaining CE marking and achieving commercialization in Europe during the reporting period, contributing to revenue growth [1] Group 3: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management [1] - The group's joint venture, 4C Medical Technologies, Inc., completed a Series D financing round, leading to a decrease in the company's equity stake in 4C Medical, which generated income from the perceived sale of part of its equity [1]
港股异动 | 心通医疗-B(02160)午前涨超4% 将于本月底发布业绩 预期上半年净亏损同比减少不低于83%